Novo Nordisk Stock Is Downgraded. There's a ‘Tough Path Ahead.

Core Insights - U.S. prescriptions for Novo's Ozempic and Wegovy drugs are experiencing stagnation according to Morgan Stanley analysts [1] Company Summary - The stagnation in prescriptions indicates potential challenges for Novo in maintaining growth for its key products Ozempic and Wegovy [1]